developed an antibody-drug conjugate (84-EBET) targeting CEACAM6, which delivered degradation agents to pancreatic tumors and significantly enhanced the efficacy of chemotherapy and immunotherapy (51). Here, CEACAM6 is linked to pancreatic neoplasm.